Search
DS-2325a
go.drugbank.com/drugs/DB18134InvestigationalDS-2325a is an inhibitor of kallikrein 5 under development for the treatment of Netherton Syndrome.
Recombinant Cholera Toxin B Subunit
go.drugbank.com/drugs/DB11643ApprovedInvestigationalRecombinant Cholera Toxin B Subunit is an ingredient in the EMA-authorised product Dukoral.
Iothalamic acid
go.drugbank.com/drugs/DB09133ApprovedIothalamic acid is an iodine containing organic anion used as a diagnostic contrast agent.
Synonyms: 1-deoxy-1-(methylamino)-D-glucitol 5-acetamido-2,4,6 triiodo-N-methylisophthalamateACA 125
go.drugbank.com/drugs/DB05489InvestigationalAn IgG1 murine monoclonal anti-idiotype antibody (Ab2), ACA-125, was developed to bind to anti-CA 125 antibodies. … ACA-125 mimics the tumor-associated antigen CA-125, which can be detected in about 80% of ovarian carcinomas.
Pranlukast
go.drugbank.com/drugs/DB01411InvestigationalIt antagonizes or reduces bronchospasm caused, principally in asthmatics, by an allergic reaction to accidentally or inadvertently encountered allergens.
Cosibelimab
go.drugbank.com/drugs/DB15770ApprovedInvestigationalCosibelimab is a human IgG1 lambda monoclonal antibody directed against programmed death ligand-1 (PD-L1). On December 13, 2024, cosibelimab was approved by the FDA for the treatment of metastatic or locally advanced cutaneous squamous c...
KW-7158
go.drugbank.com/drugs/DB05498ExperimentalThe therapeutic effects of KW-7158 in overactive bladder may be due to the activation of A-type K(+) channels which regulate afferent neuron excitability and firing properties in the dorsal root ganglion
Epoetin delta
go.drugbank.com/drugs/DB11624ApprovedWithdrawnEpoetin Delta is an ingredient in the EMA-withdrawn product Dynepo.
Parnaparin
go.drugbank.com/drugs/DB09260ApprovedParnaparin is an heparin of low molecular weight with antithrombotic effects.
Products: FLUXUM 0.3 ML 3200 IU 2 HAZIR SIRINGA, FLUXUM 0.3 ML 3200 IU 6 HAZIR SIRINGABerahyaluronidase alfa
go.drugbank.com/drugs/DB22790ApprovedInvestigationalBerahyaluronidase alfa is a recombinant variant of human hyaluronidase designed to enhance dispersion and permeation of subcutaneously co-administered drugs. It is used in a fixed-dose combination with pembrolizumab for subcutaneous inje...